Opinion|Videos|August 30, 2024
Biomarkers as Tools in Management of Type 2 Inflammation
Author(s)Reynold A. Panettieri Jr, MD
An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.
Advertisement
Episodes in this series
- What biomarkers can reliably assess the presence of type 2 inflammation as a contributing factor in asthma or COPD?
- How can absolute eosinophil count specifically be used as a tool in this population for regimen selection? Does this biomarker have a role in predicting treatment response or patient outcomes?
Advertisement
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Advertisement
Advertisement
Trending on AJMC
1
Unanswered Questions in First- and Second-Line mCRC Care
2
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
Precision Drugs Meet Payer Realities
5